• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Consumer Cyclical·1294.TWO
Share

Hantech Bio-Technology Co., Ltd. Stocks

NT$ 56.1Last Updated 22.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 53.04M

NT$ 56.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2007 and headquartered in Yuanlin, Taiwan, Hantech Bio-Technology Co., Ltd. specializes in creating, producing, and distributing health products grounded in scientific research. The company distinguishes itself through its use of various environmentally conscious pouch packaging styles for its offerings. Under OEM and ODM collaborations, Hantech provides a range of dietary supplements available in gel, liquid, and powder forms. These supplements are presented in an extensive selection of distinctive packaging shapes, such as rectangular, curved, Z-shaped, round, wine bottle-inspired, and standing pouches.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.07.2026 13:06

BTIG analysts no longer recommend buying TripAdvisor stock. It's losing out to AI

22.07.2026 12:04

Neuralink's Valuation on the Secondary Market Soared to $42 Billion — Business Insider

22.07.2026 11:28

No Alternatives: How the Halt in Oil Exports via the CPC Will Affect Kazakhstan

22.07.2026 10:37

OpenAI's advanced models spiraled out of control and carried out an "unprecedented" hack

22.07.2026 10:30

Morning Highlights: Supermicro Shares Jumped 20%, Yen Hits 40-Year Low

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026